Literature DB >> 14695340

pp32 reduction induces differentiation of TSU-Pr1 cells.

Jonathan R Brody1, Shrihari S Kadkol, M Claire Hauer, Fatemeh Rajaii, Jessica Lee, Gary R Pasternack.   

Abstract

pp32 (ANP32A) is a nuclear phosphoprotein expressed as a nonmutated form in self-renewing cell populations and neoplastic cells. Mechanistically, pp32 may regulate pathways important in the process of differentiation as part of separate complexes inhibiting histone acetylation and regulating immediate-early and cytokine mRNA stability. Prostatic adenocarcinomas express pp32 in a differentiation related manner-well-differentiated tumors express lower levels of pp32 than poorly differentiated tumors. In benign prostate, pp32 is expressed in basal cells but not in terminally differentiated glandular cells. Based on these observations, we hypothesized that reduction of pp32 expression might be an important differentiation signal. We used anti-sense pp32 and RNAi transfection to study the effects of reduced pp32 expression in the TSU-Pr1 carcinoma cell line. pp32 reduction induced TSU-Pr1 cells to differentiate into neuronal-like cells with associated inhibition of growth. Reduction of pp32 and consequent differentiation were accompanied by a marked reduction in expression of SET, which complexes with pp32, by a marked change in acetylation status of histone H4, and by further differential expression of genes in differentiation pathways. Thus, reduction of pp32 in the undifferentiated TSU-Pr1 neoplastic cell line induces differentiation and thus may be an element of a differentiation control pathway in both normal and neoplastic cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14695340      PMCID: PMC1602226          DOI: 10.1016/S0002-9440(10)63117-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  30 in total

1.  Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein.

Authors:  S B Seo; P McNamara; S Heo; A Turner; W S Lane; D Chakravarti
Journal:  Cell       Date:  2001-01-12       Impact factor: 41.582

2.  Upregulation of p21(WAF1/CIP1) leads to morphologic changes and esterase activity in TPA-mediated differentiation of human prostate cancer cell line TSU-Pr1.

Authors:  R Sugibayashi; T Shimizu; T Suzuki; N Yamamoto; H Hamada; K Takeda
Journal:  Oncogene       Date:  2001-03-08       Impact factor: 9.867

3.  Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A.

Authors:  J M Seeling; J R Miller; R Gil; R T Moon; R White; D M Virshup
Journal:  Science       Date:  1999-03-26       Impact factor: 47.728

4.  Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.

Authors:  M E Cox; P D Deeble; S Lakhani; S J Parsons
Journal:  Cancer Res       Date:  1999-08-01       Impact factor: 12.701

5.  Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells.

Authors:  S Mori; K Murakami-Mori; B Bonavida
Journal:  Biochem Biophys Res Commun       Date:  1999-04-13       Impact factor: 3.575

6.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

Authors:  L M Butler; D B Agus; H I Scher; B Higgins; A Rose; C Cordon-Cardo; H T Thaler; R A Rifkind; P A Marks; V M Richon
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

7.  HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3' untranslated regions of cytokine and angiogenic factor mRNAs.

Authors:  L B Nabors; G Y Gillespie; L Harkins; P H King
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

8.  Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor.

Authors:  S G Carlson; E Eng; E G Kim; E J Perlman; T D Copeland; B J Ballermann
Journal:  J Am Soc Nephrol       Date:  1998-10       Impact factor: 10.121

Review 9.  Stem cell features of benign and malignant prostate epithelial cells.

Authors:  A M De Marzo; W G Nelson; A K Meeker; D S Coffey
Journal:  J Urol       Date:  1998-12       Impact factor: 7.450

10.  Protein ligands to HuR modulate its interaction with target mRNAs in vivo.

Authors:  C M Brennan; I E Gallouzi; J A Steitz
Journal:  J Cell Biol       Date:  2000-10-02       Impact factor: 10.539

View more
  4 in total

1.  Acidic nuclear phosphoprotein 32kDa (ANP32)B-deficient mouse reveals a hierarchy of ANP32 importance in mammalian development.

Authors:  Patrick T Reilly; Samia Afzal; Chiara Gorrini; Koren Lui; Yury V Bukhman; Andrew Wakeham; Jillian Haight; Teo Wei Ling; Carol C Cheung; Andrew J Elia; Patricia V Turner; Tak Wah Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-02       Impact factor: 11.205

2.  Cracking the ANP32 whips: important functions, unequal requirement, and hints at disease implications.

Authors:  Patrick T Reilly; Yun Yu; Ali Hamiche; Lishun Wang
Journal:  Bioessays       Date:  2014-08-25       Impact factor: 4.345

3.  Generation and characterization of the Anp32e-deficient mouse.

Authors:  Patrick T Reilly; Samia Afzal; Andrew Wakeham; Jillian Haight; Annick You-Ten; Kathrin Zaugg; Joanna Dembowy; Ashley Young; Tak W Mak
Journal:  PLoS One       Date:  2010-10-26       Impact factor: 3.240

4.  pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.

Authors:  Timothy K Williams; Christina L Costantino; Nikolai A Bildzukewicz; Nathan G Richards; David W Rittenhouse; Lisa Einstein; Joseph A Cozzitorto; Judith C Keen; Abhijit Dasgupta; Myriam Gorospe; Gregory E Gonye; Charles J Yeo; Agnieszka K Witkiewicz; Jonathan R Brody
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.